Imatinib Mesylate Coupons & Prices

Imatinib Mesylate FAQs

How much does Imatinib Mesylate cost without insurance?

Imatinib Mesylate may cost around $9,004.08 for 30, 400MG Tablet. The cost could be high without insurance coverage, although the exact retail cost can vary depending on the dosage and quantity prescribed. Using a SingleCare Imatinib Mesylate discount card may help you to save on your prescription medication. You could pay only $70.74 for 30, 400mg Tablet of Imatinib Mesylate when you use a SingleCare discount card at neighborhood pharmacies.

How much does Imatinib Mesylate cost with insurance?

The cost of Imatinib Mesylate with insurance may vary based on the type of insurance plan you are enrolled in. Contact your insurance provider or your pharmacist to find out exactly how much Imatinib Mesylate costs under your plan. SingleCare can help you to easily save on your Imatinib Mesylate purchases. You could pay only $70.74 for 30, 400mg Tablet of Imatinib Mesylate when you use a SingleCare Imatinib Mesylate pharmacy discount card.

Does Medicare cover Imatinib Mesylate and how much does it cost?

Imatinib Mesylate is currently covered by most, if not all, Medicare plans. Your typical copay cost under Medicare can range from $15 to $8,200. The exact cost with Medicare can vary. Using SingleCare may help you to save on your Imatinib Mesylate prescription. In some cases, SingleCare may even be more affordable than your Medicare plan. Take your SingleCare savings card to your local pharmacy to compare prices.

What is the brand name of Imatinib Mesylate?

Imatinib Mesylate is a generic prescription drug manufactured by various companies, including Mylan, Apotex, and Teva Pharmaceuticals. The brand-name version of this drug is Gleevec, which is currently manufactured by Novartis Pharmaceuticals.

What is Imatinib Mesylate?

Imatinib Mesylate is an FDA-approved generic prescription drug typically used to treat certain cancers of the blood, such as acute lymphoblastic leukemia and chronic myeloid leukemia. This medication is a chemotherapy drug that works by slowing or stopping the growth of cancer cells.

Imatinib Mesylate is available as an oral tablet that should be taken with a meal and a full glass of water, usually once or twice daily. Do not crush the tablets. If you have trouble swallowing the tablets whole, you may dissolve them in a glass of water or apple juice. Your doctor will recommend an appropriate dose for you based on an assessment of your current medical condition, other drugs you are currently taking, and your response to treatment.

Avoid eating grapefruit or drinking grapefruit juice while using this medication unless your doctor or pharmacist says you may do so safely. You should also tell your doctor about other medical conditions you may have or other medications you may be taking, including prescription drugs, over-the-counter medications, and herbal supplements. Imatinib Mesylate may interact with grapefruit and certain medications, which can alter the effectiveness or increase the risk of side effects of Imatinib Mesylate or other drugs. 

What are the side effects of Imatinib Mesylate?

Imatinib Mesylate may cause unwanted side effects, such as an upset stomach, nausea, vomiting, diarrhea, headaches, muscle or joint pain, muscle cramps, dizziness, blurred vision, or drowsiness. If any of these effects persist or get worse, consult with your doctor or pharmacist.

Serious side effects of Imatinib Mesylate include reduced blood cell or platelet counts, heart problems, liver problems, kidney problems, perforations in the stomach or intestines, and decreased thyroid hormone levels, among others. Tell your doctor immediately if you experience serious signs or symptoms, such as easier bleeding or bruising than normal, unusual tiredness, sudden explained weight gain, swelling in the ankles or feet, shortness of breath, fast heartbeat, unexplained loss of appetite, or yellowing of the eyes and skin. 

This is not a complete list of side effects. Seek medical advice from your healthcare provider on the risks and benefits involved with using Imatinib Mesylate.